Long-term outcomes of hematopoietic stem cell transplantation in patients with multiple sclerosis

Takeaway

  • Autologous hematopoietic stem cell transplantation (aHSCT) prevents worsening disability in most patients and induces lasting improvement in disability in patients with relapsing remitting multiple sclerosis (RRMS).

Why this matters

  • Intense immunosuppression followed by aHSCT (aims to induce cell self-tolerance via extensive renewal of the immune system) has been explored as a treatment strategy for aggressive MS; however, outcome data has generally been limited to short-term follow-up.

  • The positive long-term clinical outcomes of aHSCT in MS may significantly impact future treatment and management strategies for this condition, improving long-term quality of life and emotional outcomes for patients.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.